Kailera launches with $400M series A and clutch of Chinese obesity drugs

Kailera Therapeutics has launched into the increasingly crowded obesity space with a portfolio of assets acquired from China and $400 million in series A funds.

The Massachusetts- and California-based biotech is led by former Cerevel Therapeutics CEO Ron Renaud. Kailera may only be stepping into the spotlight today, but it secured the ex-China rights to four GLP-1 drugs from Jiangsu Hengrui Pharmaceuticals back in May.